Compare Medtronic PLC (MDT) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Tilray Brands Inc — how do they compare? Medtronic PLC trades at $87.92 (market cap $112.24B), while Tilray Brands Inc trades at $3.61 (market cap $530.54M). The key difference: Medtronic PLC is far larger — about 211.6× Tilray Brands Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Tilray Brands Inc for 31 Days on average.
| MDT | TLRY | |
|---|---|---|
Market Cap | $112.24B | $530.54M |
Volume | 105,663,236 | 9,099,075 |
Sector | Health | Health |
52-Week High | $105.35 | $21.00 |
52-Week Low | $73.75 | $3.57 |
Typical Hold Time | 63 Days | 31 Days |
Enterprise Value | $131.58B | $684.46M |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, showing bearish technical signals despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q3 2026 results pending, while maintaining robust profitability margins of 65% gross and 14% net. Recent news highlights the company's 49-year dividend growth streak and new product approvals, though technical indicators show selling pressure with the stock trading near support at $85.
MDT presents a compelling value opportunity with a 3.2% dividend yield and 14% upside to the $97.80 consensus target, though near-term technical weakness and increasing debt levels warrant caution. The company's consistent earnings beats and medical device market leadership support long-term growth, while regulatory approvals for new systems provide catalysts.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
